BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15191558)

  • 1. BRAF point mutations in primary melanoma show different prevalences by subtype.
    Sasaki Y; Niu C; Makino R; Kudo C; Sun C; Watanabe H; Matsunaga J; Takahashi K; Tagami H; Aiba S; Horii A
    J Invest Dermatol; 2004 Jul; 123(1):177-83. PubMed ID: 15191558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF kinase gene V599E mutation in growing melanocytic lesions.
    Loewe R; Kittler H; Fischer G; Faé I; Wolff K; Petzelbauer P
    J Invest Dermatol; 2004 Oct; 123(4):733-6. PubMed ID: 15373778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tandem BRAF mutations in primary invasive melanomas.
    Thomas NE; Alexander A; Edmiston SN; Parrish E; Millikan RC; Berwick M; Groben P; Ollila DW; Mattingly D; Conway K
    J Invest Dermatol; 2004 May; 122(5):1245-50. PubMed ID: 15140228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.
    Lang J; MacKie RM
    J Invest Dermatol; 2005 Sep; 125(3):575-9. PubMed ID: 16117801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
    Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
    J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High BRAF mutation frequency does not characterize all melanocytic tumor types.
    Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
    Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
    Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
    J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
    Baiter M; Schuler G; Hartmann A; Schneider-Stock R; Heinzerling L
    Dermatology; 2015; 231(2):127-33. PubMed ID: 26138035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
    Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
    Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
    Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
    J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
    J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
    Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.